‘Highly effective’: COVID-19 vaccines reduced risk of heart failure, other cardiovascular complications after infection – Cardiovascular Business

All vaccinated adults received a vaccine developed by Oxford/AstraZeneca, BioNTech/Pfizer, Janssen or Moderna from January to July 2021. Researchers focused on early outcomes from the first 30 days following SARS-CoV-2 infection as well as later outcomes from days 31 to 365 following infection.

Overall, the team found that COVID-19 vaccines were highly effective in protecting the cardiovascular health of adults with SARS-CoV-2 infections. Vaccinated adults with a SARS-CoV-2 infection experienced a substantial reduction in their risk of a variety of cardiovascular and thromboembolic complications compared to unvaccinated adults with a SARS-CoV-2 infection. This included significantly reduced short- and long-term risks of heart failure, venous thromboembolism and arterial thrombosis/thromboembolism. The impact was greatest during those initial 30 days following infection.

In line with previous studies, our findings suggest a potential benefit of vaccination in reducing the risk of post-COVID-19 thromboembolic and cardiac complications, the authors wrote. We included broader populations, estimated the risk in both acute and post-acute infection phases and replicated these using four large independent observational databases. By pooling results across different settings, we provided the most up-to-date and robust evidence on this topic.

Besora and colleagues added that these findings highlight yet another benefit of COVID-19 vaccination, though they did say additional research is still needed to learn more about this subject.

Click here to read their full analysis.

Read more from the original source:

'Highly effective': COVID-19 vaccines reduced risk of heart failure, other cardiovascular complications after infection - Cardiovascular Business